ArticleFrontiers in allergy2025
Symptom burden in patients with chronic rhinosinusitis with nasal polyps or global airway disease prior to biologic treatment: a qualitative study of patients' experiences.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-compassion, self-care, and rhinitis control assessment in patients with allergic rhinitis: a latent profile and mediation analysis.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP), is a prevalent inflammatory airway disease associated with type 2 inflammation. When CRSwNP coexist with asthma, the condition is referred to as global air disease (GAD). People how lives with CRSwNP or GAD often report a high symptom burden, for example persistent nasal obstruction, impaired smell and taste, disturbed sleep, fatigue, and reduced well-being. While these burdens have been quantified through clinical outcomes and patient-reported outcome measures (PROMs), there is limited qualitative research exploring how these peoples experience living with CRSwNP or GAD in their daily lives. The aim of the study was to describe the impact of CRSwNP or GAD on patients' everyday lives before the initiation of biologic treatment. Methods: A descriptive qualitative interview study was conducted with 13 patients diagnosed with CRSwNP or GAD. Semi-structured interviews were analyzed using qualitative content analyzed as described by Graneheim and Lundman, resulting in the identification of thematic categories reflecting participants' lived experiences. Results: Five categories were identified: (1) Conclusion: This study showed that patients with CRSwNP or GAD experienced a substantial symptom burden, sensory loss, impaired work ability, and reduced social participation, all of which profoundly affected their daily lives. Many relied on prednisolone for temporary relief despite being aware of its serious side effects. The extensive impact of CRSwNP made participants hopeful that biologic therapy could provide more stable symptom control and help them regain a more "normal" life. CRSwNP or GAD is a multifaceted condition that affects patients' emotional, psychological, and social well-being. These findings highlight the importance of adopting a holistic treatment approach, including consideration of psychosocial support to address the broader consequences of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.